Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cell Therapy Deals A "Strategic Priority" For Shire

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The recent earnings season was a reminder that Shire PLC, along with other specialist drug developers such as Celgene Inc., are comfortably positioned in a high-revenue-growth world that most big pharma have forgotten about.
Advertisement

Related Content

Disappointing Provenge Sales Stir Doubts About Demand
Advanced BioHealing To Bring Regeneration To Shire
U.K. Biotech Renovo's Future On The Line As Phase III Lead Crashes
Shire/TKT: The Price of Diversification
Shire/TKT: The Price of Diversification

Topics

Advertisement
UsernamePublicRestriction

Register

PS004801

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel